Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes ...

Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

As per the company’s regulatory filing, Kristy is currently available in the European Union and Canada markets from 2022.

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...